In collaboration with
The London Edge Life Sciences initiative highlights London’s pre-eminent international position as a financial centre and shows how the Exchange’s suite of markets underpins our unique global position for companies in the life sciences sector.
Located at the heart of global finance, London offers unrivalled access to a wide range of industry experience and a deep pool of international capital. London’s expertise in the life sciences sector means that your business is understood by analysts and investors. This unique event will showcase international listed and pre-IPO companies in the life sciences sector to a select audience of UK institutional investors, coupled with a practical and relevant seminar for companies on how to make the most of their listing.
Day 1 will include a Capital Markets Day showcasing international listed and pre-IPO companies to a targeted group of institutional investors, indicating the interest in this sector.
On Day 2, companies who are considering their options for an IPO will have the opportunity to listen to, and interact with advisors and listed companies, on how best to position themselves to take advantage of the world’s largest capital market.
Who should attend?
- Buy-side institutional investors
- Sell-side analysts
- VC investors
- Pre-IPO companies
- Private companies
About the London Stock Exchange
Our Main Market is home to many of the world’s largest life sciences companies. Our commitment to life sciences companies is demonstrated by the existence of the techMARK mediscience market segment in 2001. techMARK mediscience groups together specialist life sciences companies on the Exchange’s Main Market, providing a focus for investors and the opportunity for peer group comparison. London is the only Exchange with an index dedicated to growth companies in the life sciences sector – the FTSE™ techMARK mediscience index provides investors in small and mid-sized companies from this industry with the only accurate and independent measurement tool of this market.
AIM® our market for smaller companies, is the world’s most successful growth market. Many smaller companies in various stages of product development have realised the benefits of AIM.
Its simplified entry criteria and more flexible regulatory regime make it the ideal choice for life sciences companies just starting out.
Companies on both the Main Market and AIM can be confident they are developing on markets renowned for their high standards of regulation and integrity. Our markets offer companies the opportunity to enhance their status and global visibility.
Supported by
